SciBase letter from the CEO number 4: Updated strategy and securing our long-term capital needs
This summer’s great news, the FDA approval of Nevisense, was an important milestone in the history of the Company. We are very pleased and proud of our achievement, and following this we have together with the board further developed our strategy. The updated strategy includes new clinical applications built on our existing Nevisense platform, and an increased focus on sales and growth where of course the US will play an important role. To implement this more ambitious growth strategy we communicated already this autumn that we were investigating financing options for the strategy. Last